Group items tagged

The purpose of the Aging Interventions Testing Program (ITP) is to test, under standardized conditions in multiple sites, potential intervention strategies which may decelerate the rate of aging in mammals. The rate of aging is to be measured by lifespan extension and/or improvements in health at later ages due to the intervention. The ITP has used life span as its primary outcome for an intervention, with limited studies on end-of-life pathologies and selected tests of health across the lifespan (health span). This FOA calls for renewal and expansion of the ITP with the following goals: 1. Continue to test compounds for effects on lifespan; 2. Increase analysis of pharmacodynamics and pharmacokinetics of compounds proposed for lifespan studies, including studies of optimal effective dose; 3. Increase histology and pathophysiology analyses at time-of-death; 4. Increase focused studies of health span on selected compounds; 5. Establish a data coordinating center.

The goal of this Funding Opportunity Announcement (FOA) is to support research focused on understanding the role of senescence in brain aging and in Alzheimer's disease (AD). This FOA encourages research projects addressing critical knowledge gaps in our understanding of the neurobiology of senescence through cutting-edge techniques, cross-disciplinary collaborations, and/or conceptual innovation, leveraging what is known about senescence in peripheral tissues to learn more about brain aging. Developing a clear understanding of the mechanisms driving aging processes in the brain, including senescence, is essential for combating age-related neurodegenerative diseases.

This funding opportunity announcement (FOA) invites applications for basic research to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in both normal aging and Alzheimer's disease (AD). Research is sought that will characterize the extent to which basic behavioral and neural processes involved in decision-making are differentially impacted in normal aging and AD, investigate the influence of social factors on decision-making, and investigate the decision-making factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse. The FOA also invites applications to apply basic research on the processes involved in decision-making to the design of decision-supportive interventions for midlife and older adults with and without AD. Specific opportunities include the development of decision-supportive interventions to leverage cognitive, emotional and motivational strengths of these populations; tools to assess decisional capacity; strategies for simplifying choices and offering better defaults; and the promotion of timely adoption of optimal delegation practices (e.g., power of attorney, living wells, etc.).

This funding opportunity announcement (FOA) invites applications for basic research to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in both normal aging and Alzheimer's disease (AD). Research is sought that will characterize the extent to which basic behavioral and neural processes involved in decision-making are differentially impacted in normal aging and AD, investigate the influence of social factors on decision-making, and investigate the decision-making factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse. The FOA also invites applications to apply basic research on the processes involved in decision-making to the design of decision-supportive interventions for midlife and older adults with and without AD. Specific opportunities include the development of decision-supportive interventions to leverage cognitive, emotional and motivational strengths of these populations; tools to assess decisional capacity; strategies for simplifying choices and offering better defaults; and the promotion of timely adoption of optimal delegation practices (e.g., power of attorney, living wells, etc.).

In order to continue to attract new generations of talented investigators, the Glenn/AFAR Scholarships for Research in the Biology of Aging have been established.  The program is designed to give students enrolled in MD, DO, PhD, or combined-degree programs the opportunity to conduct a three-to-six-month research project focused on biomedical research in aging.  The program aims to give students the chance to learn more about the field of aging research, as well as increase their understanding of the challenges involved in improving the quality of life for older people.

This announcement solicits applications for Early Detection of Vision Problems in Young Children. The purpose of this grant program is to increase the detection and diagnosis of visual impairment in children aged five (5) years and younger in five (5) States by enhancing the capacity of the State public health agencies to use and apply quality improvement principles and practices to implement universal vision screening for preschool-aged children. Funds will be provided to a single entity to convene a learning collaborative comprised of five States to work together jointly to identify challenges, interventions, implementation, and measurement related to implementing universal vision screening for preschool-aged children. To facilitate collaborative learning and quality improvement efforts, the awardee may ask each of the five participating States to consider forming a vision screening quality improvement team. The optimal team would include representatives from the State Title V program, State early childhood and education programs, State health surveillance and information systems (e.g., immunization registry), community health centers, pediatric primary and vision specialty care, and family organizations. The awardee may convene the State teams to apply rapid test cycles to increase coordination among the relevant State agencies, providers, and community organizations to support the tracking, disseminating, and spreading of innovative and promising practices necessary to achieve the program purpose. Program Aim: By 2018, increase by 20 percent over 2011-2012 levels, the proportion of children aged five (5) years and younger who receive vision screening and diagnosis in five (5) States according to the National Survey of Children¿s Health measure. http://www.childhealthdata.org/learn/NSCH To accomplish the program purpose and aim, it is expected the awardee will: · Establish a multidisciplinary project advisory group made up of stakeholders includin

This Funding Opportunity Announcement (FOA) is a phased innovation initiative to facilitate multi-omics/integrative approaches to identify omics profiles associated with protection against multiple aging conditions, with exceptional health span, and to refine strategies for utilizing these profiles for therapeutics development. Specifically, a phased innovation cooperative agreement mechanism (UH2/UH3) involving an interdisciplinary research team will be used to support a single project that will conduct integrative analysis of person-specific multiple omics measurements (e.g., transcriptomics, proteomics, metabolomics) generated across multiple tissues; the multi-omic profiling should be conducted on individuals from extensively phenotyped cohorts with substantial numbers of long-lived individuals with characteristics of exceptionally healthy aging and appropriate controls.

The Clinician-Scientists Transdisciplinary Aging Research (Clin-STAR) Coordinating Center is seeking to fund pilot or planning grants that aim to stimulate new collaborations focused on the development of clinical aging research projects. A major goal of this effort is to bridge junior and senior researchers from different disciplines and institutions in order to stimulate new areas of clinical aging research. Funding may be used to collect preliminary data in emerging and understudied areas of aging-related clinical research. The funding also provides opportunities to build mentee/mentor relationships and content expertise for the junior investigator. The Clin-STAR Coordinating Center has set aside $160,000 to fund at least 3 projects. Size and number of awards will depend on the nature of the proposals.

In a collaborative effort, the Arthritis National Research Foundation (ANRF) and the American Federation for Aging Research (AFAR) are seeking grant applications that focus on studying the underlying mechanisms of the aging process as it relates to arthritis.

The National Institute on Aging intends to publish a Funding Opportunity Announcement (FOA) to solicit applications for a Clinician-Scientists Transdisciplinary Aging Research (Clin-STAR) Coordinating Center. This Center will organize activities and provide research resources for clinician-investigators across the United States who are focusing their careers on aging research. This FOA is intended to build upon the substantial investments made by NIA through the GEMSSTAR program and related career development efforts by supporting expanded activities to reach a broader community of clinician-investigators. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in September 2018 with an expected application due date in November 2018. This FOA will utilize the U24 activity code for resource-related research projects through cooperative agreement. Details of the planned FOA are provided below.

This Funding Opportunity Announcement (FOA) invites research applications addressing cellular and molecular mechanisms that regulate aging of the reproductive tissues, including the niche, in gonads, reproductive accessory organs, and the reproductive neuroendocrine system. This FOA will accept basic mechanistic studies in human subjects and vertebrate animals. Research supported by this initiative should enhance knowledge of mechanisms that regulate aging of the reproductive system.

Despite significant scientific advancements made in substance use disorder research over the last century, the causes and consequences of drug use in later life remain poorly understood. The intent of this funding opportunity announcement is to support innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. This FOA encourages research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations.

This FOA encourages exploratory/developmental research applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) as described in NOT-OD-15-137. Also Listed under (R01)

Despite significant scientific advancements made in substance use disorder research over the last century, the causes and consequences of drug use in later life remain poorly understood. The intent of this funding opportunity announcement is to support innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. This FOA encourages research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations.

The National Institute on Aging is seeking applications to develop systems biology approaches to understand the basic biology underpinning neurodegeneration which might ultimately contribute to Alzheimer's disease or related dementias, using non-mammalian laboratory animal models. It is expected that research carried under the auspices of this FOA will lead to discovery of new mechanisms that provoke neurodegeneration and to new molecular pathways that might be involved in causing, amplifying or protecting against neurodegeneration. Applications should propose to use established non-mammalian laboratory animals which have a history of contributions to our understanding of neurobiology or aging biology.  

The Progeria Research Foundation is seeking proposals from principal researchers for projects related to Hutchinson-Gilford Progeria Syndrome (HGPS), a rare, fatal, "premature aging" disease that affects children who die of heart disease at an average age of 13 - the same heart disease that affects millions of normal aging adults (atherosclerosis). The program supports research projects with specific relevance to HGPS and that show promise for contributing to the scientific or clinical advancement in this field of study. Grants are awarded in three categories:  Innovator Awards, Established Investigator Awards, and Specialty Awards. 1) Innovator Awards: Two-year grants of up to $75,000 a year are available  to  investigators eagerto embark on new lines of investigation and  produce enough preliminary data to be competitive for longer-term funding by NIH and/or other agencies. 2) Established Investigator Awards: Three-year grants of up to $100,000 a year are available to senior investigators established either in the field of HGPS or a field that can be directly applied to it. 3) Specialty Awards: These grants are awarded for smaller, more technology-driven projects, including sequencing, screening potential drugs, obtaining cell lines (including IPSCs), and preparation of antibodies.  Funding amounts and lengths are flexible.

Purpose This FOA is intended to support research on lupus through a longitudinal study designed to follow an established, US-based., population-based cohort with lupus (systemic lupus erythematosus {SLE} and skin lupus) of all ages to determine over time: o The treatment, health care access, and natural history (severity, morbidity, mortality, etc.) of cohort members, o Factors (including genetic and other biological factors such as antibody levels) associated with these outcomes, and o The above by categories of research interest (e.g., age, gender, race/ethnic group). Knowledge of such information for lupus, which is associated with strong age/sex/race disparities and has had little public health research, can help identify missed opportunities for better treatment, help identify new disease phenotypes based on progression of disease, and help identify factors associated with progression that may play a role in secondary and tertiary prevention. 

The purpose of this FOA is to invite pilot/feasibility (R03) projects on: 1) descriptive studies to identify putative juvenile protective factors, 2) experimental studies to test hypotheses about their effects on aging and 3) translational studies to explore the potential risks and benefits of maintaining or modulating the level of juvenile protective factors in adult life. Juvenile protective factors are physiological factors that maintain or enhance certain functions across all or some stages of post-natal maturation, but which diminish or disappear during transitions between developmental stages (e.g., infancy, adiposity rebound, adrenarche, puberty, growth cessation). This FOA is uniquely focused on studies which involve comparisons between post-natal developmental stages or pre- vs. post-maturational changes to identify potential juvenile protective factors and their effects on aging. Pilot studies in in vitro models, in laboratory animals or in humans may be proposed.

Sponsored by The Glenn Foundation for Medical Research, in collaboration with the American Federation for Aging Research (AFAR), the "Breakthroughs in Gerontology (BIG)" initiative provides timely support to a small number of research projects that are building on early discoveries that show translational potential for clinically-relevant strategies, treatments and therapeutics, addressing human aging and health span.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate interdisciplinary health-disparities research related to aging that considers the role that stress, stress response, and stress resilience play in differential health outcomes in priority health disparity populations in the U.S.In particular, this FOA seeks applications proposing to clarify pathways linking stress and aging-relevant health outcomes (e.g. mortality, cognitive impairment, multiple chronic conditions, disability, quality of life) through the investigation of links between environmental, sociocultural, behavioral, and biological factors.

The goal of this FOA is to encourage applications from institutions/organizations proposing to develop, refine, and pilot test innovative strategies to improve diabetes management in pre-teens (ages 10-12), adolescents (ages 13-18) and/or young adults (ages 19-30) with type 1 diabetes.